LuciMob — Mobocertinib 40 mg, 120 pcs, Lucius

LuciMob — Mobocertinib Capsules 40 mg, 120 Capsules

Product code: 508

87165₴ 95032₴ -8% On order · from 10 days

Analogues

LuciMob Moboxen
1
Active ingredient
Dosage form Capsules
Capsules per pack 120

LuciMob is a specialized targeted antineoplastic agent belonging to the tyrosine kinase inhibitor (TKI) class, indicated for the treatment of locally advanced or metastatic non-small cell lung cancer. The active pharmaceutical ingredient is mobocertinib at a strength of 40 mg supplied as hard gelatin capsules (Mobocertinib Capsules 40 mg). The product is developed and manufactured by Lucius Pharmaceuticals.

Mobocertinib is a selective, oral, irreversible tyrosine kinase inhibitor specifically targeting epidermal growth factor receptor (EGFR) exon 20 insertion mutations. Such mutations traditionally exhibit high resistance to classical first- and second-generation EGFR TKIs. Mobocertinib selectively blocks these mutant kinase forms, suppressing tumor cell proliferation and inducing apoptosis in lung cancer with the corresponding genetic profile.

Supplied in a package containing 120 capsules of 40 mg. Intended exclusively for oral administration under the strict supervision of an oncologist.

Key Clinical Features and Advantages of LuciMob 40 mg:

  • ✅ Targeted EGFR Exon 20 Action: Specifically designed to overcome challenging exon 20 insertion mutations.
  • ✅ Proven Clinical Efficacy: Therapeutic activity in pretreated patients with rare NSCLC forms.
  • ✅ Convenient Oral Dosing: Taken orally once daily regardless of food intake.
  • ✅ Precise Strength: The 40 mg capsules provide the required daily dosing regimen (160 mg).
  • ✅ Lucius Pharmaceuticals Standards: High-quality, accessible generic alternative to the originator product (Exkivity).

LuciMob is supplied as hard gelatin capsules for oral administration.

Qualitative and Quantitative Composition per Capsule:

  • Active Ingredient: Mobocertinib (as mobocertinib succinate) — 40 mg.
  • Excipients: Microcrystalline cellulose, lactose monohydrate, croscarmellose sodium, magnesium stearate, colloidal anhydrous silica. Capsule shell: gelatin, titanium dioxide, colorants.

Packaging and Presentation: Hard capsules, 40 mg strength. Each package contains 120 capsules along with prescribing information. Labeled with LuciMob (Mobocertinib Capsules 40 mg) and Lucius Pharmaceuticals corporate graphics.

Pharmacodynamics:
Mobocertinib is an irreversible EGFR tyrosine kinase inhibitor with high selectivity against EGFR and HER2 exon 20 insertion mutations. EGFR exon 20 insertions cause constitutive kinase activation, driving tumor growth. Mobocertinib covalently binds to cysteine-797 within the EGFR kinase domain, inhibiting phosphorylation and blocking downstream survival signaling pathways in tumor cells.

Pharmacokinetics:

  • Absorption: Following oral administration, mobocertinib absorption is relatively slow; peak plasma concentration (Tmax) is achieved within approximately 4 to 5 hours. Food intake has no clinically significant effect on absorption.
  • Distribution: Human plasma protein binding is high (approx. 99%).
  • Metabolism: Extensively metabolized in the liver, primarily via cytochrome P450 enzymes (mainly CYP3A4 and CYP2C19).
  • Elimination: Excreted predominantly via feces (approx. 76% as metabolites) and renally (approx. 3%). Terminal elimination half-life (T1/2) averages approximately 15 to 18 hours.

LuciMob is indicated in adult patients for:

  • Non-Small Cell Lung Cancer (NSCLC): Treatment of adult patients with locally advanced or metastatic non-small cell lung cancer harboring EGFR exon 20 insertion mutations as determined by an approved test, whose disease has progressed on or after platinum-based chemotherapy.

LuciMob is administered orally once daily every day at approximately the same time.

Dosing Regimen:
The recommended standard dose is 160 mg (four 40 mg capsules) once daily.

Administration Guidelines:
Capsules should be swallowed whole with water; do not break, crush, open, or chew. Can be taken with or without food. If a dose is missed or vomiting occurs after ingestion, take the next dose at the scheduled time (do not double doses).

Administration of LuciMob is contraindicated in:

  • Hypersensitivity: Known hypersensitivity to mobocertinib or any excipient (including lactose intolerance).
  • Pregnancy and Lactation: Strictly contraindicated in pregnant or breastfeeding women.
  • Pediatric Population: Safety and efficacy in patients under 18 years have not been established.
  • Severe Hepatic or Renal Impairment: Pronounced liver or kidney dysfunction.
  • Cardiac Rhythm Disorders: Baseline significant QT interval prolongation.

Mobocertinib is metabolized via CYP3A4 and CYP2C19 enzymes:

  • Strong and Moderate CYP3A4 Inhibitors (ketoconazole, itraconazole, clarithromycin, ritonavir, grapefruit juice): Significantly elevate mobocertinib plasma concentrations and toxicity risks (including QT interval prolongation). Avoid concurrent use.
  • Strong CYP3A4 Inducers (rifampicin, carbamazepine, phenytoin, St. John's Wort): Significantly decrease mobocertinib blood concentrations and reduce efficacy. Avoid concurrent use.
  • QT-Prolonging Drugs: Co-administration requires extreme caution due to arrhythmia risks.

Pregnancy:
LuciMob is contraindicated during pregnancy. Based on its mechanism of action, mobocertinib may cause fetal harm and embryotoxicity. Females of reproductive potential and male partners must utilize effective reliable contraception during treatment and for at least 1 month following the final dose.

Lactation:
Excretion of mobocertinib into human breast milk is unstudied. Breastfeeding must be discontinued during treatment.

The most frequent and clinically significant adverse reactions include:

  • Gastrointestinal Tract (Very Common): Diarrhea (a primary adverse effect requiring early antidiarrheal therapy and hydration), nausea, vomiting, abdominal pain, decreased appetite, stomatitis.
  • Cardiovascular System: QT interval prolongation on ECG (regular ECG monitoring and electrolyte management required).
  • Dermatologic Reactions: Rash, dry skin, paronychia, pruritus.
  • General Disorders: Fatigue, asthenia, musculoskeletal pain.
  • Laboratory Abnormalities: Elevated blood creatinine, electrolyte imbalances.

Symptoms:
Specific acute overdose symptoms of mobocertinib are unestablished. Anticipated manifestations include exacerbated adverse reactions (severe diarrhea, nausea, pronounced QT interval prolongation).

Treatment:
No specific antidote exists. In case of overdose, discontinue treatment, monitor cardiac activity (ECG), and initiate supportive and symptomatic care.

Storage Requirements for LuciMob 40 mg:

  • 🌡️ Temperature Range: Store in original packaging in a dry place protected from light at temperatures below 30 °C.
  • 👶 Safety Precautions: Keep strictly out of reach of children (cytotoxic antineoplastic agent).
  • ⏳ Shelf Life: Stated on carton and blister pack. Don't use past expiration date. Prescription-only oncology medicine.

To verify authenticity of genuine LuciMob 40 mg manufactured by Lucius Pharmaceuticals, inspect the following security and visual features:

  • ✅ Security Hologram & Scratch Code: Outer carton features an official Lucius Pharmaceuticals anti-counterfeit holographic seal with a scratch-off verification code for online validation via the manufacturer's official portal.
  • ✅ Corporate Branding: High-resolution printing displaying Lucius Pharmaceuticals graphics, Mobocertinib Capsules 40 mg, and 120 Capsules count.
  • ✅ Factory Markings: Clearly printed Batch No., Mfg. Date, and Exp. Date matching across outer packaging and internal blister packs.
  • ✅ Prescribing Information: Includes an official product leaflet inside the outer carton.
On order · from 10 days
100% original product
Delivery across Ukraine
1

Notice. The information on this page is for reference only and does not replace medical consultation. Always consult a healthcare professional and read the manufacturer's instructions before using any medicine. Self-medication may be dangerous. Information updated: 15.11.2026

Customer reviews

No reviews yet

Your review can be the first!

Contact us

Choose a convenient way to contact

We work daily from 9:00 to 20:00